1. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
- Author
-
Magaret, Craig, Li, Li, deCamp, Allan, Rolland, Morgane, Juraska, Michal, Williamson, Brian, Ludwig, James, Molitor, Cindy, Benkeser, David, Luedtke, Alex, Simpkins, Brian, Heng, Fei, Sun, Yanqing, Carpp, Lindsay, Bai, Hongjun, Dearlove, Bethany, Giorgi, Elena, Jongeneelen, Mandy, Brandenburg, Boerries, McCallum, Matthew, Bowen, John, Veesler, David, Sadoff, Jerald, Gray, Glenda, Roels, Sanne, Vandebosch, An, Stieh, Daniel, Le Gars, Mathieu, Vingerhoets, Johan, Grinsztejn, Beatriz, Goepfert, Paul, de Sousa, Leonardo, Silva, Mayara, Casapia, Martin, Losso, Marcelo, Gaur, Aditya, Bekker, Linda-Gail, Garrett, Nigel, Truyers, Carla, Van Dromme, Ilse, Swann, Edith, Marovich, Mary, Follmann, Dean, Neuzil, Kathleen, Corey, Lawrence, Greninger, Alexander, Roychoudhury, Pavitra, Hyrien, Ollivier, Gilbert, Peter, and Little, Susan
- Subjects
Humans ,Ad26COVS1 ,COVID-19 ,SARS-CoV-2 ,Vaccine Efficacy ,Amino Acids ,Antibodies ,Viral ,Antibodies ,Neutralizing - Abstract
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p
- Published
- 2024